State Street SPDR S&P Biotech ETF
XBI
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 1 Iron Street Boston MA United States of America 2210
- IPO Date
- Feb 6, 2006
- CIK
- 0001064642
- Website
- ssga.com
- Similar Companies
- Business
- SPDR S&P Biotech ETF (XBI) is an exchange-traded fund managed by State Street Global Advisors that seeks to track the performance, before fees and expenses, of the S&P Biotechnology Select Industry Index. The fund provides exposure to the biotechnology segment of the S&P Total Market Index through a modified equal-weighted portfolio comprising approximately 134 U.S. biotechnology companies across large-, mid-, and small-cap market capitalizations; it emphasizes unconcentrated industry exposure and quarterly rebalancing while focusing on pure biotech plays with limited pharmaceutical overlap. Top holdings as of September 2025 include CRISPR Therapeutics AG (2.26%), Exelixis Inc. (1.99%), AbbVie Inc. (1.99%), Madrigal Pharmaceuticals Inc. (1.94%), and Moderna Inc. (1.93%), alongside other leaders in gene editing, oncology, and therapeutics such as Revolution Medicines Inc., Ionis Pharmaceuticals Inc., Amgen Inc., Regeneron Pharmaceuticals, and United Therapeutics Corp. Launched on January 31, 2006, and headquartered in Boston, Massachusetts, XBI operates primarily in the U.S. market, targeting investors seeking targeted exposure to biotechnology innovation in areas like drug development, genetic engineering, gene therapy, targeted protein degradation, and rare disease treatments. The ETF holds approximately $7.85 billion in assets under management with a gross expense ratio of 0.35% and serves institutional and retail investors focused on high-growth, volatile sectors within healthcare. In recent developments, XBI has benefited from a surge in biotech sector mergers and acquisitions activity through 2025, with the ETF rising 23% year-to-date amid Big Pharma pipeline replenishment efforts and consolidation waves impacting its small- and mid-cap heavy holdings. Portfolio adjustments in 2025 included new positions in emerging biotech firms such as Capricor Therapeutics, GRAIL, Tourmaline Bio, LENZ Therapeutics, and Taysha Gene Therapies, reflecting quarterly rebalancing and market dynamics; additionally, the fund hit new 52-week highs in December 2025 amid broader biotech recovery from a four-year slump. Heightened M&A expectations into Q4 2025 and key FDA decisions on portfolio companies further position XBI for potential volatility and growth.